AmCad BioMed Corporation (TPEX:4188)
Taiwan
· Delayed Price · Currency is TWD 13.00
+0.05 (0.39%)
Mar 10, 2026, 9:15 AM CST
AmCad BioMed Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 30.44 | 53.11 | 65.26 | 61.63 | 85.79 | Upgrade
|
| Revenue Growth (YoY) | -42.69% | -18.62% | 5.88% | -28.16% | 34.17% | Upgrade
|
| Cost of Revenue | 20.41 | 20.17 | 24.23 | 23.58 | 25.13 | Upgrade
|
| Gross Profit | 10.02 | 32.93 | 41.02 | 38.05 | 60.67 | Upgrade
|
| Selling, General & Admin | 50.87 | 53.82 | 50.89 | 48.39 | 46.59 | Upgrade
|
| Research & Development | 47.11 | 43.78 | 44.12 | 54 | 50.95 | Upgrade
|
| Operating Expenses | 97.98 | 97.6 | 95.01 | 102.34 | 97.44 | Upgrade
|
| Operating Income | -87.96 | -64.66 | -53.99 | -64.3 | -36.77 | Upgrade
|
| Interest Expense | -0.09 | -0.18 | -0.12 | -0.12 | -0.14 | Upgrade
|
| Interest & Investment Income | 5.8 | 6.18 | 4.71 | 4.72 | 3.73 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.02 | 0.09 | 1.7 | 1.98 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.84 | 5.93 | 6.32 | 3.66 | 4.38 | Upgrade
|
| EBT Excluding Unusual Items | -71.4 | -52.72 | -42.98 | -54.35 | -26.82 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.03 | 0 | 0.02 | 0 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.19 | -0.17 | -0.01 | -0.08 | Upgrade
|
| Other Unusual Items | - | - | 0 | - | - | Upgrade
|
| Pretax Income | -71.4 | -52.88 | -43.15 | -54.34 | -26.89 | Upgrade
|
| Income Tax Expense | -0.02 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -71.39 | -52.88 | -43.15 | -54.34 | -26.89 | Upgrade
|
| Minority Interest in Earnings | 15.67 | 2.3 | -2.17 | 0.86 | 1.35 | Upgrade
|
| Net Income | -55.72 | -50.58 | -45.31 | -53.49 | -25.54 | Upgrade
|
| Net Income to Common | -55.72 | -50.58 | -45.31 | -53.49 | -25.54 | Upgrade
|
| Shares Outstanding (Basic) | 63 | 58 | 53 | 53 | 53 | Upgrade
|
| Shares Outstanding (Diluted) | 63 | 58 | 53 | 53 | 53 | Upgrade
|
| Shares Change (YoY) | 9.72% | 8.42% | 0.01% | - | 0.09% | Upgrade
|
| EPS (Basic) | -0.88 | -0.88 | -0.85 | -1.01 | -0.48 | Upgrade
|
| EPS (Diluted) | -0.88 | -0.88 | -0.85 | -1.01 | -0.48 | Upgrade
|
| Free Cash Flow | -47.44 | -54.57 | -41.89 | -34.81 | -41.3 | Upgrade
|
| Free Cash Flow Per Share | -0.75 | -0.95 | -0.79 | -0.65 | -0.78 | Upgrade
|
| Gross Margin | 32.93% | 62.02% | 62.87% | 61.73% | 70.71% | Upgrade
|
| Operating Margin | -288.97% | -121.77% | -82.73% | -104.33% | -42.86% | Upgrade
|
| Profit Margin | -183.06% | -95.24% | -69.44% | -86.79% | -29.78% | Upgrade
|
| Free Cash Flow Margin | -155.85% | -102.76% | -64.20% | -56.48% | -48.14% | Upgrade
|
| EBITDA | -72.16 | -51.94 | -41.26 | -51.48 | -23.46 | Upgrade
|
| EBITDA Margin | -237.07% | -97.81% | -63.22% | -83.52% | -27.35% | Upgrade
|
| D&A For EBITDA | 15.8 | 12.72 | 12.73 | 12.82 | 13.31 | Upgrade
|
| EBIT | -87.96 | -64.66 | -53.99 | -64.3 | -36.77 | Upgrade
|
| EBIT Margin | -288.97% | -121.77% | -82.73% | -104.33% | -42.86% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.